MRNA Stock Game Over? Not Quite, As Moderna Boosts Its 2023 Outlook Investor’s Business Daily

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

Moderna’s third-quarter sales beat expectations, though revenue tumbled 44% to $1.8 billion. Last year, Moderna’s Covid vaccine brought in about $6.7 billion in sales. That includes about $600 million in deferred revenue from a partnership with Gavi, a vaccine alliance that distributes vaccines to the world’s poorest countries. Moderna also said it increased its market share to 48% vs. competitors Pfizer (PFE) and Novavax (NVAX). Due in large part to its COVID-19 vaccine, biotech company Moderna’s stock price has grown considerably over the last five years. Most recently, Moderna has been making the news for a promising cancer vaccine that’s currently being tested.

  1. In general, when interest rates go up, Bond prices typically drop, and vice versa.
  2. Let’s see which option might offer us the best return down the road.
  3. Stéphane Bancel has an approval rating of 92% among the company’s employees.
  4. Over the past month, there’s been a 14.23% rise in the Zacks Consensus EPS estimate.

And speaking of Pfizer, a company executive recently said COVID-19 could move from pandemic to endemic by 2024. Some regions might reach this point earlier (as soon as next year), but it’s clear the coronavirus threat is far from over. As Singh wrote, Moderna’s “non-COVID-19 pipeline is still 2-3 years away from commercial” and its Covid-19 vaccine will “start facing financial pressure as early as 2023,” according to MarketWatch. To find the best stocks to buy and watch, check out IBD Stock Lists.

Sign up for a brokerage account on Public

But over the long term, Moderna has the pipeline, technology, and resources to keep on winning. And that means investors who stick around for a while should score a big win, too. (I have twice been jabbed with SpikeVax and have no financial interest in the securities mentioned in this post). In November 2020, I estimated that its Covid-19 vaccine — now branded SpikeVax — could add as much as $35 billion to Moderna’s revenues. But MRNA stock has a poor EPS Rating of 4, reflecting recent losses.

Such information is time sensitive and subject to change based on market conditions and other factors. You assume full responsibility for any trading decisions you make based upon the market data provided, and Public is not liable for any loss caused directly or indirectly by your use of such information. Market data is provided solely for informational and/or educational purposes only.

Shares are now below their 200-day line, but surged above their 50-day line on Dec. 14. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. You can get this information through your online broker, on Moderna’s investor relations website or on financial information sites.

Analysts don’t expect a return to massive pandemic-era growth until 2025. That year, they expect strong sales of vaccines for Covid, RSV and the flu. The cancer vaccine reduced the likelihood cancer would return or patients would die after about three years.

Is Moderna’s stock too cheap to pass up?

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances.

Zacks Research

Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Public Investing is not registered. Securities products offered by Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

Neither Public Investing nor any of its affiliates is a bank. The pipeline also includes Moderna’s personalized cancer vaccine, a highly anticipated shot being developed with Merck to target different tumor types, along with a flu vaccine. “Our assumption is everyone who has gotten their booster in 2023 will at least get their booster also in 2024 and beyond,” Moderna CCO Arpa Garay said during the earnings call. Garay added that the company expects to see “some increase in the overall Covid market” as patients become more understanding of annual vaccine recommendations. Overall, the earnings report was stellar, and the stock jumped on the results.

Company Close Updates

No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

Moderna scored Emergency Use Authorization and finished the year with a 434% share gain. That’s after the company reported billions of dollars in revenue and profit every quarter. There’s no shortage of potential for Moderna, but as with any biotech company, there’s the risk that these vaccines don’t pan out or are unable to garner significant easymarkets market share. And without some strong pillars to build around after COVID-19 revenue inevitably drops off, there could be a decline in the financials, not to mention a drop in the stock’s popularity. For the last three months of 2021, Moderna’s revenue topped $7.2 billion and soundly beat analysts’ expectations of $6.8 billion.

Bonds with higher yields or offered by issuers with lower credit ratings generally carry a higher degree of risk. All fixed income securities are subject to price change and availability, and yield is subject to change. Bond ratings, if provided, are third party opinions on the overall bond’s credit worthiness at the time the rating is assigned. Ratings are not recommendations to purchase, hold, or sell securities, and they do not address the market value of securities or their suitability for investment purposes. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”).

Leave a Reply